Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis in ALK-rearranged non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Pailler, Emma [1 ]
Faugeroux, Vincent [1 ]
Oulhen, Marianne [2 ]
Forcato, Claudio [3 ]
Laporte, Melanie [4 ]
Lecluse, Yann [4 ]
Lacroix, Ludovic [4 ]
NgoCamus, Maud [4 ]
Nicotra, Claudio [4 ]
Remon, Jordi [4 ]
Mezquita, Laura [4 ]
Planchard, David [4 ]
Soria, Jean-Charles [4 ]
Manaresi, Nicolo [3 ]
Besse, Benjamin [4 ]
Farace, Francoise [1 ]
机构：
[1] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France
[2] INSERM, Gustave Roussy, U981, Villejuif, France
[3] Menarini Silicon Biosyst, Castel Maggiore, Italy
[4] Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3654
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China
    Puyuan Xing
    Shouzheng Wang
    Qiang Wang
    Di Ma
    Xuezhi Hao
    Mengzhao Wang
    Yan Wang
    Li Shan
    Tao Xin
    Li Liang
    Hongge Liang
    Yang Du
    Zhaohui Zhang
    Junling Li
    Targeted Oncology, 2019, 14 : 325 - 333
  • [42] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Pan, Yue
    Deng, Chao
    Qiu, Zhenhua
    Cao, Chenghui
    Wu, Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Immune exhaustion of tumor microenvironment mediates crizotinib resistance in ALK rearranged advanced non small cell lung cancer
    Zhang, Yongchang
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Treatment After Crizotinib Resistance in ALK plus Non-Small-Cell Lung Cancer
    Kazaz, Seher N.
    Oztop, Ilhan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2017, 27 (01): : 60 - 68
  • [45] Molecular imaging as a predictive biomarker response to Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Medina-Ornelas, S.
    Garcia-Perez, F.
    Arrieta-Rodriguez, O.
    Barron-Barron, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S568 - S568
  • [46] The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer
    Seo, S.
    Woo, C. G.
    Lee, D. H.
    Choi, J.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1667 - 1668
  • [47] Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 255 - 268
  • [48] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [49] Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
    Kanaan, Zeyad
    Kloecker, Goetz H.
    Paintal, Ajit
    Perez, Cesar A.
    ONCOTARGETS AND THERAPY, 2015, 8 : 885 - 892
  • [50] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Pilling, Amanda B.
    Aisner, Dara L.
    Kutateladze, Tatiana G.
    Le, Anh T.
    Weickhardt, Andrew J.
    Kondo, Kimi L.
    Linderman, Derek J.
    Heasley, Lynn E.
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1472 - 1482
12345